Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms

Azacitidine (AZA) is a hypomethylating drug used to treat disorders associated with myelodysplasia and related neoplasms. Approximately 50 % of patients do not respond to AZA and have very poor outcomes. There is thus great interest in identifying predictive biomarkers for AZA responsiveness. We sea...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2016-11, Vol.104 (5), p.566-573
Main Authors: Monika Belickova, M., Merkerova, Michaela Dostalova, Votavova, Hana, Valka, Jan, Vesela, Jitka, Pejsova, Barbora, Hajkova, Hana, Klema, Jiri, Cermak, Jaroslav, Jonasova, Anna
Format: Article
Language:English
Subjects:
Azacitidine - pharmacology
Azacitidine - therapeutic use
Bone Marrow Cells - metabolism
Cell Proliferation - genetics
Hematology
Humans
Leukemia, Myeloid, Acute - genetics
Leukemia, Myelomonocytic, Chronic - genetics
Medicine
Medicine & Public Health
Myelodysplastic Syndromes - drug therapy
Myelodysplastic Syndromes - genetics
Oncology
Original Article
Ribosomal Proteins - genetics
Transcriptome - drug effects
Treatment Failure
Up-Regulation - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Azacitidine (AZA) is a hypomethylating drug used to treat disorders associated with myelodysplasia and related neoplasms. Approximately 50 % of patients do not respond to AZA and have very poor outcomes. There is thus great interest in identifying predictive biomarkers for AZA responsiveness. We searched for specific genes whose expression level was associated with response status. Using microarrays, we analyzed gene expression patterns in bone marrow CD34 + cells in serial samples from 32 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia with myelodysplasia-related changes before and during the AZA therapy. At baseline, a comparison of the responders and non-responders showed 52 differentially expressed genes ( P  
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-016-2058-3